Thank you to Health Choice for sharing this article on their Facebook page. From CNBC, the business channel.
More than $1.5 billion vanished from vaccine developer Novavax's market value almost instantaneously Thursday afternoon after a late-stage trial of its vaccine for a common respiratory virus failed.
It's the worst nightmare of investors in biotech, but also a serious blow to public health. The company was trying to tackle a problem that's thwarted medicine for more than half a century.
RSV — or respiratory syncytial virus — is usually not a big deal for healthy people, but for two populations, babies and older adults, it can be extremely serious. According to the Centers for Disease Control and Prevention, RSV is the most common cause of pneumonia and another respiratory condition called bronchiolitis in babies under 1 year old in the U.S.
Each year it hospitalizes more than 50,000 kids under age 5, and leads to 14,000 deaths among adults older than 65. It was that older population in which Novavax ran its 11,000-patient study. Its vaccine failed to provide any protection, sending the stock down more than 80 percent.
"This has been a 30- or 40-year effort to get to where Novavax is, in terms of a candidate that goes into phase 3 trials," said Dr. Mark Feinberg, CEO of the International AIDS Vaccine Initiative, and former chief public health and science officer for Merck Vaccines, in a telephone interview Friday. "There's been a longstanding desire to have an RSV vaccine."